



	MD (Pathol	<b>/ Chopra</b> ogy & Microbiology) & Consultant Pathologist	Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist		
NAME AGE/ GENDER COLLECTED BY	<b>: Mr. SANJEEV SHARMA</b> : 48 YRS/MALE : SURJESH		PATIENT ID REG. NO./LAB NO.	: 1581148 <b>: 012408150016</b>	
REFERRED BY BARCODE NO. CLIENT CODE. CLIENT ADDRESS	: : 01515100 : KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD, AMBALA (		REGISTRATION DATE COLLECTION DATE REPORTING DATE	: 15/Aug/2024 10:36 AM : 15/Aug/2024 10:43AM : 15/Aug/2024 11:40AM	
Test Name		Value	Unit	Biological Reference interval	
	C		TRY/BIOCHEMISTR DFILE : BASIC	Y	
CHOLESTEROL TOTA by CHOLESTEROL O>		185.8	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0	
TRIGLYCERIDES: SER by GLYCEROL PHOSE	RUM PHATE OXIDASE (ENZYMATIC)	119.1	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL ( by SELECTIVE INHIBIT		44.63	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: 5 by CALCULATED, SPE		117.35	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLESTE by CALCULATED, SPI	ROL: SERUM ECTROPHOTOMETRY	141.17 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTEROL by calculated, spe		23.82	mg/dL	0.00 - 45.00	
TOTAL LIPIDS: SERUI	M	490.7	mg/dL	350.00 - 700.00	
CHOLESTEROL/HDL by CALCULATED, SPE	ratio: serum	4.16	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0	
LDL/HDL RATIO: SEF	RUM	2.63	RATIO	LOW RISK: 0.50 - 3.0	
	an	é	shopra		

KOS Diagnostic Lab (A Unit of KOS Healthcare)

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

回知思济

673

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com

 www.koshealthcare.com
 www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





	Dr. Vinay Cł MD (Pathology & Chairman & Cor			(Pathology)
NAME	: Mr. SANJEEV SHARMA			
AGE/ GENDER	: 48 YRS/MALE		PATIENT ID	: 1581148
COLLECTED BY	: SURJESH		REG. NO./LAB NO.	: 012408150016
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 15/Aug/2024 10:36 AM
BARCODE NO.	:01515100		COLLECTION DATE	: 15/Aug/2024 10:43AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		<b>REPORTING DATE</b>	: 15/Aug/2024 11:40AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	, AMBALA CANT	Т	
Test Name		Value	Unit	Biological Reference interval
by CALCULATED, SPECTROPHOTOMETRY				MODERATE RISK: 3.10 - 6.0
				HIGH RISK: $> 6.0$
TRIGLYCERIDES/HDL RATIO: SERUM by calculated, spectrophotometry		2.67 <sup>L</sup>	RATIO	3.00 - 5.00

INTERPRETATION:

1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

